{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:49:20Z","timestamp":1782470960199,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00292-026-01576-5","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:32:40Z","timestamp":1782131560000},"page":"273-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leitlinienentwicklung zur MRD-Diagnostik der AML als Blaupause f\u00fcr solide Tumoren","Guideline development for MRD diagnostics in AML as a\u00a0blueprint for solid tumors"],"prefix":"10.1007","volume":"47","author":[{"given":"Michael","family":"Heuser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wickenhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Oevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"12","key":"1576_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner\u00a0H, Wei\u00a0AH, Appelbaum\u00a0FR, Craddock\u00a0C, DiNardo\u00a0CD, Dombret\u00a0H et\u00a0al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"11","key":"1576_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0RP, Borowitz\u00a0MJ, Calvo\u00a0KR, Kvasnicka\u00a0HM et\u00a0al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"26","key":"1576_CR3","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser\u00a0M, Freeman\u00a0SD, Ossenkoppele\u00a0GJ, Buccisano\u00a0F, Hourigan\u00a0CS, Ngai\u00a0LL et\u00a0al (2021) 2021 Update on MRD in acute myeloid leukemia: a\u00a0consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"issue":"3","key":"1576_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70097","volume":"9","author":"HC Hupe","year":"2025","unstructured":"Hupe\u00a0HC, Wienecke\u00a0CP, Bartels\u00a0S, Schipper\u00a0E, Le\u00dfmann\u00a0J, Lasch\u00a0A et\u00a0al (2025) Cell-free DNA for detection and monitoring of extramedullary AML relapse. Hemasphere. 2025 Mar 10;9(3):e70097.https:\/\/doi.org\/10.1002\/hem3.70097","journal-title":"Hemasphere"},{"key":"1576_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1396187","volume":"15","author":"M Bauer","year":"2024","unstructured":"Bauer\u00a0M, Monecke\u00a0A, Hackl\u00a0H, Wilfer\u00a0A, Jaekel\u00a0N, Bl\u00e4ker\u00a0H et\u00a0al (2024) Association of immune evasion in myeloid sarcomas with disease manifestation and patients\u2019 survival. Front Immunol 15:1396187. https:\/\/doi.org\/10.3389\/fimmu.2024.1396187","journal-title":"Front Immunol"},{"key":"1576_CR6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031480","author":"J Cloos","year":"2026","unstructured":"Cloos\u00a0J, Valk\u00a0PJM, Thiede\u00a0C, D\u00f6hner\u00a0K, Roboz\u00a0GJ, Wood\u00a0BL et\u00a0al (2025) Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Blood. 2026 Mar 12;147(11):1147-1167. https:\/\/doi.org\/10.1182\/blood.2025031480","journal-title":"Blood Journal"},{"issue":"3","key":"1576_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.seminhematol.2025.06.004","volume":"62","author":"KJ Croese","year":"2025","unstructured":"Croese\u00a0KJ, Cloos\u00a0J, Tettero\u00a0JM (2025) Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications. Semin Hematol 62(3):167\u2013176. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.004","journal-title":"Seminars in Hematology"},{"issue":"1","key":"1576_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/asheducation-2016.1.356","volume":"2016","author":"G Ossenkoppele","year":"2016","unstructured":"Ossenkoppele\u00a0G, Schuurhuis\u00a0GJ (2016) MRD in AML: does it already guide therapy decision-making? Hematology Am Soc Hematol Educ Program 2016(1):356\u2013365. https:\/\/doi.org\/10.1182\/asheducation-2016.1.356","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"1576_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis\u00a0GJ, Heuser\u00a0M, Freeman\u00a0S, B\u00e9n\u00e9\u00a0MC, Buccisano\u00a0F, Cloos\u00a0J et\u00a0al (2018) Minimal\/measurable residual disease in AML: a\u00a0consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u20131291. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"issue":"Supplement 1","key":"1576_CR10","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.1182\/blood-2025-7051","volume":"146","author":"JA Lucero","year":"2025","unstructured":"Lucero\u00a0JA, Perusini\u00a0M, Bankar\u00a0A, Davidson\u00a0M, Richard-Carpentier\u00a0G, Schimmer\u00a0A et\u00a0al (2025) Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A\/NPM1\/WT1 mutation. Blood 146(Supplement 1):7051\u20137051. https:\/\/doi.org\/10.1182\/blood-2025-7051","journal-title":"Blood"},{"issue":"4","key":"1576_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/BF01700374","volume":"70","author":"A Macedo","year":"1995","unstructured":"Macedo\u00a0A, Orf\u00e3o\u00a0A, Vidriales\u00a0MB, L\u00f3pez-Berges\u00a0MC, Valverde\u00a0B, Gonz\u00e1lez\u00a0M et\u00a0al (1995) Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 70(4):189\u2013194. https:\/\/doi.org\/10.1007\/BF01700374","journal-title":"Ann Hematol"},{"issue":"1","key":"1576_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.73","volume":"93","author":"BL Wood","year":"2020","unstructured":"Wood\u00a0BL (2020) Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. Curr Protoc Cytom 93(1):e73. https:\/\/doi.org\/10.1002\/cpcy.73","journal-title":"Curr Protoc Cytom"},{"issue":"1","key":"1576_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000676","volume":"6","author":"JM Tettero","year":"2022","unstructured":"Tettero\u00a0JM, Freeman\u00a0S, Buecklein\u00a0V, Venditti\u00a0A, Maurillo\u00a0L, Kern\u00a0W et\u00a0al (2022) Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. Hemasphere 6(1):e676. https:\/\/doi.org\/10.1097\/HS9.0000000000000676","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"1576_CR14","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/blood-2023-181709","volume":"142","author":"LL Ngai","year":"2023","unstructured":"Ngai\u00a0LL, Hanekamp\u00a0D, Kelder\u00a0A, Scholten\u00a0W, Carbaat-Ham\u00a0J, Fayed\u00a0MMHE et\u00a0al (2023) The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia. Blood 142(Supplement 1):1572\u20131572. https:\/\/doi.org\/10.1182\/blood-2023-181709","journal-title":"Blood"},{"issue":"24","key":"1576_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262411885","volume":"26","author":"JM Ruijter","year":"2025","unstructured":"Ruijter\u00a0JM, Van Den Hoff\u00a0MJB (2025) Analysis of qPCR Data: From PCR Efficiency to Absolute Target Quantity. International Journal of Molecular Sciences 26(24):11885. https:\/\/doi.org\/10.3390\/ijms262411885","journal-title":"IJMS"},{"issue":"3","key":"1576_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1053\/j.semdp.2023.04.004","volume":"40","author":"J Zhang","year":"2023","unstructured":"Zhang\u00a0J, Oak\u00a0J (2023) Challenges of detecting measurable\/minimal disease in acute leukemia. Seminars in Diagnostic Pathology 40(3):216\u2013220. https:\/\/doi.org\/10.1053\/j.semdp.2023.04.004","journal-title":"Seminars in Diagnostic Pathology"},{"issue":"19","key":"1576_CR17","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman\u00a0J, Potter\u00a0N, Ivey\u00a0A, Jovanovic\u00a0J, Runglall\u00a0M, Freeman\u00a0SD et\u00a0al (2024) Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19):1931\u20131936. https:\/\/doi.org\/10.1182\/blood.2023023096","journal-title":"Blood"},{"issue":"5","key":"1576_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey\u00a0A, Hills\u00a0RK, Simpson\u00a0MA, Jovanovic\u00a0JV, Gilkes\u00a0A, Grech\u00a0A et\u00a0al (2016) Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med 374(5):422\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1507471","journal-title":"N Engl J Med"},{"issue":"19","key":"1576_CR19","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.2019001425","volume":"134","author":"FG R\u00fccker","year":"2019","unstructured":"R\u00fccker\u00a0FG, Agrawal\u00a0M, Corbacioglu\u00a0A, Weber\u00a0D, Kapp-Schwoerer\u00a0S, Gaidzik\u00a0VI et\u00a0al (2019) Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood 134(19):1608\u20131618. https:\/\/doi.org\/10.1182\/blood.2019001425","journal-title":"Blood"},{"issue":"5","key":"1576_CR20","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3324\/haematol.2018.205955","volume":"104","author":"RL Levine","year":"2019","unstructured":"Levine\u00a0RL, Valk\u00a0PJM (2019) Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica 104(5):868\u2013871. https:\/\/doi.org\/10.3324\/haematol.2018.205955","journal-title":"Haematologica"},{"issue":"16","key":"1576_CR21","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol\u00a0F, Gabdoulline\u00a0R, Liebich\u00a0A, Klement\u00a0P, Schiller\u00a0J, Kandziora\u00a0C et\u00a0al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132(16):1703\u20131713. https:\/\/doi.org\/10.1182\/blood-2018-02-829911","journal-title":"Blood"},{"issue":"9","key":"1576_CR22","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser\u00a0M, Heida\u00a0B, B\u00fcttner\u00a0K, Wienecke\u00a0CP, Teich\u00a0K, Funke\u00a0C et\u00a0al (2021) Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv 5(9):2294\u20132304. https:\/\/doi.org\/10.1182\/bloodadvances.2021004367","journal-title":"Blood Adv"},{"issue":"7","key":"1576_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/ng.3304","volume":"47","author":"JC Taylor","year":"2015","unstructured":"Taylor\u00a0JC, Martin\u00a0HC, Lise\u00a0S, Broxholme\u00a0J, Cazier\u00a0JB, Rimmer\u00a0A et\u00a0al (2015) Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet 47(7):717\u2013726. https:\/\/doi.org\/10.1038\/ng.3304","journal-title":"Nat Genet"},{"issue":"8","key":"1576_CR24","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jmoldx.2020.04.213","volume":"22","author":"RR Singh","year":"2020","unstructured":"Singh\u00a0RR (2020) Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors. J\u00a0Mol Diagn 22(8):994\u20131007. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.04.213","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"13","key":"1576_CR25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic\u00a0M, Grob\u00a0T, Hanekamp\u00a0D, Kavelaars\u00a0FG, Al Hinai\u00a0A, Zeilemaker\u00a0A et\u00a0al (2018) Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med 378(13):1189\u20131199. https:\/\/doi.org\/10.1056\/NEJMoa1716863","journal-title":"N Engl J Med"},{"issue":"3","key":"1576_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood.2023022697","volume":"144","author":"CP Wienecke","year":"2024","unstructured":"Wienecke\u00a0CP, Heida\u00a0B, Venturini\u00a0L, Gabdoulline\u00a0R, Kr\u00fcger\u00a0K, Teich\u00a0K et\u00a0al (2024) Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Blood 144(3):296\u2013307. https:\/\/doi.org\/10.1182\/blood.2023022697","journal-title":"Blood"},{"issue":"6","key":"1576_CR27","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3324\/haematol.2020.260133","volume":"106","author":"A Lesieur","year":"2020","unstructured":"Lesieur\u00a0A, Thomas\u00a0X, Nibourel\u00a0O, Boissel\u00a0N, Fenwarth\u00a0L, De Botton\u00a0S et\u00a0al (2020) Minimal residual disease monitoring in acute myeloid leukemia with non-A\/B\/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica 106(6):1767\u20131769. https:\/\/doi.org\/10.3324\/haematol.2020.260133","journal-title":"haematol"},{"issue":"13","key":"1576_CR28","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","volume":"6","author":"NJ Short","year":"2022","unstructured":"Short\u00a0NJ, Kantarjian\u00a0H, Ravandi\u00a0F, Konopleva\u00a0M, Jain\u00a0N, Kanagal-Shamanna\u00a0R et\u00a0al (2022) High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006\u20134014. https:\/\/doi.org\/10.1182\/bloodadvances.2022007378","journal-title":"Blood Adv"},{"issue":"6","key":"1576_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","volume":"9","author":"NJ Short","year":"2025","unstructured":"Short\u00a0NJ, Aldoss\u00a0I, DeAngelo\u00a0DJ, Konopleva\u00a0M, Leonard\u00a0J, Logan\u00a0AC et\u00a0al (2025) Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv 9(6):1442\u20131451. https:\/\/doi.org\/10.1182\/bloodadvances.2024015441","journal-title":"Blood Advances"},{"issue":"1","key":"1576_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-024-01078-8","volume":"14","author":"P Hirsch","year":"2024","unstructured":"Hirsch\u00a0P, Lambert\u00a0J, Bucci\u00a0M, Deswarte\u00a0C, Boudry\u00a0A, Lambert\u00a0J et\u00a0al (2024) Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study. Blood Cancer J 14(1):97\u201397. https:\/\/doi.org\/10.1038\/s41408-024-01078-8","journal-title":"Blood Cancer J"},{"key":"1576_CR31","doi-asserted-by":"publisher","unstructured":"(2023) RESOLVE P medicine for leukaemia treatment. Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across Europe (RESOLVE). https:\/\/cordis.europa.eu\/project\/id\/101136502https:\/\/doi.org\/10.3030\/101136502","DOI":"10.3030\/101136502"},{"issue":"2","key":"1576_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3343\/alm.2018.38.2.147","volume":"38","author":"E Lee","year":"2018","unstructured":"Lee\u00a0E, Lee\u00a0KJ, Park\u00a0H, Chung\u00a0JY, Lee\u00a0MN, Chang\u00a0MH et\u00a0al (2018) Clinical Implications of Quantitative JAK 2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms. Ann Lab Med 38(2):147\u2013154. https:\/\/doi.org\/10.3343\/alm.2018.38.2.147","journal-title":"Ann Lab Med"},{"issue":"Supplement 1","key":"1576_CR33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168835","volume":"140","author":"L L","year":"2022","unstructured":"L\u00a0L, Naseem\u00a0S, Rastogi\u00a0P, Jain\u00a0A, Malhotra\u00a0P (2022) Study of JAK 2 V617F allele Burden By Droplet Digital PCR in BCR-ABL1 Negative Myeloproliferative Neoplasms and Its Implications on Disease Phenotype. Blood 140(Supplement 1):12270\u201312270. https:\/\/doi.org\/10.1182\/blood-2022-168835","journal-title":"Blood"},{"key":"1576_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2026.106073","volume":"171","author":"SK Germans","year":"2026","unstructured":"Germans\u00a0SK, Weinberg\u00a0OK, Chen\u00a0W, Cantu\u00a0M, Chen\u00a0M, Oliver\u00a0D et\u00a0al (2026) Correlation of NPM1 immunohistochemistry with mutation subtypes, clinicopathologic variables and molecular testing in AML with NPM1 mutation. Hum Pathol Rep 171:106073. https:\/\/doi.org\/10.1016\/j.humpath.2026.106073","journal-title":"Hum Pathol"},{"issue":"8","key":"1576_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/PAI.0000000000000804","volume":"28","author":"A Gupta","year":"2020","unstructured":"Gupta\u00a0A, Sazawal\u00a0S, Mahapatra\u00a0M, Pati\u00a0HP, Saxena\u00a0R (2020) Calreticulin Mutation by Immunohistochemistry: Can It Replace PCR? Appl Immunohistochem Mol Morphol 28(8):621\u2013626. https:\/\/doi.org\/10.1097\/PAI.0000000000000804","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"1576_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.pathol.2018.11.007","volume":"51","author":"R M\u00f3zes","year":"2019","unstructured":"M\u00f3zes\u00a0R, G\u00e1ng\u00f3\u00a0A, Sul\u00e1k\u00a0A, Vida\u00a0L, Reiniger\u00a0L, Tim\u00e1r\u00a0B et\u00a0al (2019) Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms. Pathology 51(3):301\u2013307. https:\/\/doi.org\/10.1016\/j.pathol.2018.11.007","journal-title":"Pathology"},{"issue":"1","key":"1576_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00984-9","volume":"9","author":"AE Boukouris","year":"2025","unstructured":"Boukouris\u00a0AE, Michaelidou\u00a0K, Joosse\u00a0SA, Charpidou\u00a0A, Mavroudis\u00a0D, Syrigos\u00a0KN et\u00a0al (2025) A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer. NPJ Precis Oncol 9(1):178. https:\/\/doi.org\/10.1038\/s41698-025-00984-9","journal-title":"npj Precis Onc"},{"issue":"7","key":"1576_CR38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok\u00a0TS, Wu\u00a0YL, Ahn\u00a0MJ, Garassino\u00a0MC, Kim\u00a0HR, Ramalingam\u00a0SS et\u00a0al (2017) Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer. N Engl J Med 376(7):629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"issue":"6","key":"1576_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard\u00a0FC, Mayer\u00a0EL, Park\u00a0YH, Janni\u00a0W, Ma\u00a0C, Cristofanilli\u00a0M et\u00a0al (2025) First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. N Engl J Med 393(6):569\u2013580. https:\/\/doi.org\/10.1056\/NEJMoa2502929","journal-title":"N Engl J Med"},{"issue":"12","key":"1576_CR40","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie\u00a0J, Wang\u00a0Y, Loree\u00a0JM, Cohen\u00a0JD, Wong\u00a0R, Price\u00a0T et\u00a0al (2025) Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat Med 31(12):4291\u20134300. https:\/\/doi.org\/10.1038\/s41591-025-04030-w","journal-title":"Nat Med"},{"issue":"1","key":"1576_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68350-6","volume":"14","author":"J Claus","year":"2024","unstructured":"Claus\u00a0J, De Smet\u00a0D, Breyne\u00a0J, Wesolowski\u00a0J, Himpe\u00a0U, Demedts\u00a0I et\u00a0al (2024) Patient-centric thresholding of Cobas\u00ae EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer. Sci Rep 14(1):18191. https:\/\/doi.org\/10.1038\/s41598-024-68350-6","journal-title":"Sci Rep"},{"key":"1576_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221096878","volume":"14","author":"V Caputo","year":"2022","unstructured":"Caputo\u00a0V, De Falco\u00a0V, Ventriglia\u00a0A, Famiglietti\u00a0V, Martinelli\u00a0E, Morgillo\u00a0F et\u00a0al (2022) Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Ther Adv Med Oncol 14:17588359221096878. https:\/\/doi.org\/10.1177\/17588359221096878","journal-title":"Ther Adv Med Oncol"},{"key":"1576_CR43","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.279","author":"C Lee","year":"2025","unstructured":"Lee\u00a0C, Kim\u00a0S, Kim\u00a0S, Park\u00a0T, Kim\u00a0M, Keam\u00a0B et\u00a0al (2025) Preferential Sensitivity of the EGFR L858M\/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. Cancer Res Treat. https:\/\/doi.org\/10.4143\/crt.2025.279","journal-title":"Cancer Res Treat"},{"key":"1576_CR44","doi-asserted-by":"crossref","unstructured":"Ciardiello D, Martini G, Boscolo Bielo L, Pietrantonio F, Raimondi A, Manca P, et\u00a0al. Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE\u20112 GOIM trial. Ann Oncol. 2025 Dec 22;S0923\u20137534(25)06334\u20113. https:\/\/doi.org\/10.1016\/j.annonc.2025.12.014 PubMed PMID: 41443411.","DOI":"10.1016\/j.annonc.2025.12.014"},{"issue":"8","key":"1576_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/app10082895","volume":"10","author":"G De Luca","year":"2020","unstructured":"De Luca\u00a0G, Lastraioli\u00a0S, Conte\u00a0R, Mora\u00a0M, Genova\u00a0C, Rossi\u00a0G et\u00a0al (2020) Performance of the OncomineTM Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice. Applied Sciences 10(8):2895. https:\/\/doi.org\/10.3390\/app10082895","journal-title":"Applied Sciences"},{"issue":"1","key":"1576_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13058-025-02055-0","volume":"27","author":"M Chaki","year":"2025","unstructured":"Chaki\u00a0M, Benrashid\u00a0M, Puri\u00a0S, Sivakumar\u00a0S, Sokol\u00a0ES, Briceno\u00a0JM et\u00a0al (2025) Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations. Breast Cancer Res 27(1):122\u2013122. https:\/\/doi.org\/10.1186\/s13058-025-02055-0","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1576_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jmoldx.2023.10.002","volume":"26","author":"JE Gray","year":"2024","unstructured":"Gray\u00a0JE, Han\u00a0JY, Telaranta-Keerie\u00a0A, Huang\u00a0X, Kohlmann\u00a0A, Hodge\u00a0R et\u00a0al (2024) Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non\u2013Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic. J\u00a0Mol Diagn 26(1):73\u201384. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.10.002","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"1","key":"1576_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jmoldx.2023.10.002","volume":"26","author":"JE Gray","year":"2024","unstructured":"Gray\u00a0JE, Han\u00a0JY, Telaranta-Keerie\u00a0A, Huang\u00a0X, Kohlmann\u00a0A, Hodge\u00a0R et\u00a0al (2024) Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non\u2013Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic. J\u00a0Mol Diagn 26(1):73\u201384. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.10.002","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"8","key":"1576_CR49","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert\u00a0T, Henriksen\u00a0TV, Christensen\u00a0E, Sharma\u00a0S, Salari\u00a0R, Sethi\u00a0H et\u00a0al (2019) Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol 5(8):1124\u20131131. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0528","journal-title":"JAMA Oncol"},{"issue":"14","key":"1576_CR50","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes\u00a0RC, Page\u00a0K, Salari\u00a0R, Hastings\u00a0RK, Armstrong\u00a0A, Ahmed\u00a0S et\u00a0al (2019) Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res 25(14):4255\u20134263. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3663","journal-title":"Clinical Cancer Research"},{"issue":"7655","key":"1576_CR51","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh\u00a0C, Birkbak\u00a0NJ, Wilson\u00a0GA, Jamal-Hanjani\u00a0M, Constantin\u00a0T, Salari\u00a0R et\u00a0al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545(7655):446\u2013451. https:\/\/doi.org\/10.1038\/nature22364","journal-title":"Nature"},{"key":"1576_CR52","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00254","volume":"10","author":"VT Ma","year":"2026","unstructured":"Ma\u00a0VT, Zhou\u00a0AY, Forati\u00a0A, Hollnagel\u00a0F, Patel\u00a0JD, Burkey\u00a0C et\u00a0al (2026) Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma. JCO Precis Oncol 10:e2500254. https:\/\/doi.org\/10.1200\/PO-25-00254","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1576_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00852-6","volume":"11","author":"A Stanciu","year":"2025","unstructured":"Stanciu\u00a0A, Agostinetto\u00a0E, Papagiannis\u00a0A, Pipinikas\u00a0C, Chevalier\u00a0A, Campbell\u00a0N et\u00a0al (2025) Personalized ctDNA detection and genomic profiling in the NeoRHEA Study. NPJ Breast Cancer 11(1):137. https:\/\/doi.org\/10.1038\/s41523-025-00852-6","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"1576_CR54","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40291-023-00670-1","volume":"27","author":"J Zhao","year":"2023","unstructured":"Zhao\u00a0J, Reuther\u00a0J, Scozzaro\u00a0K, Hawley\u00a0M, Metzger\u00a0E, Emery\u00a0M et\u00a0al (2023) Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors. Mol Diagn Ther 27(6):753\u2013768. https:\/\/doi.org\/10.1007\/s40291-023-00670-1","journal-title":"Mol Diagn Ther"},{"issue":"19","key":"1576_CR55","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1158\/1078-0432.CCR-24-1651","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura\u00a0Y, Tsukada\u00a0Y, Matsuhashi\u00a0N, Murano\u00a0T, Shiozawa\u00a0M, Takahashi\u00a0Y et\u00a0al (2024) Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay. Clin Cancer Res 30(19):4377\u20134387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1651","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1576_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40291-016-0189-0","volume":"20","author":"YY Syed","year":"2016","unstructured":"Syed\u00a0YY (2016) therascreen\u00ae EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer. Mol Diagn Ther 20(2):191\u2013198. https:\/\/doi.org\/10.1007\/s40291-016-0189-0","journal-title":"Mol Diagn Ther"},{"issue":"12","key":"1576_CR57","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/14737159.2016.1248414","volume":"16","author":"EHC Hsiue","year":"2016","unstructured":"Hsiue\u00a0EHC, Lee\u00a0JH, Lin\u00a0CC, Yang\u00a0JCH (2016) Profile of the therascreen\u00ae EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn 16(12):1251\u20131257. https:\/\/doi.org\/10.1080\/14737159.2016.1248414","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"1576_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol33040198","volume":"33","author":"MR Valerio","year":"2026","unstructured":"Valerio\u00a0MR, Sambataro\u00a0D, Martorana\u00a0F, Greco\u00a0M, Mesi\u00a0C, Gebbia\u00a0V et\u00a0al (2026) Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2\u2011Negative Breast Carcinoma: A Practical Narrative Review. Curr Oncol 33(4):198. https:\/\/doi.org\/10.3390\/curroncol33040198","journal-title":"Current Oncology"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01576-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01576-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01576-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:08:37Z","timestamp":1782468517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-026-01576-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1007\/s00292-026-01576-5","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Heuser: Forschungsf\u00f6rderung f\u00fcr die Institution: Abbvie, Bayer Pharma AG, Jazz Pharmaceuticals, Glycostem, PinotBio, Servier, Toray. Honorar: Astellas, Daiichi Sankyo, Otsuka, Pfizer, Servier. Beratung: Abbvie, Ascentage Pharma, Astellas, Daiichi Sankyo, Janssen, Miltenyi, Servier. C.\u00a0Wickenhauser, L.\u00a0Oevel und M.\u00a0Bauer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}